Synonyms: compound 62 [PMID: 31820978] | example 16 [WO2018067423A1] [1] | MSA2
Compound class:
Synthetic organic
Comment: MSA-2 is an orally bioavailable, non-nucleotide STING agonist [3]. Pharmacological activation of STING is being explored as an anti-tumour therapeutic strategy. MSA-2 has demonstrated antitumour effects in animal models. An X-ray structure of MSA-2 in complex with STING reveals that the lagand binds only when dimerised [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Altman MD, Cash BD, Chang W, Cumming JN, Haidle AM, Henderson TJ, Jewell JP, Larsen MA, Liang R, Lim J et al.. (2018)
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS. Patent number: WO2018067423A1. Assignee: Merck Sharp & Dohme Corp.. Priority date: 02/10/2017. Publication date: 12/04/2018. |
2. Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B et al.. (2020)
An orally available non-nucleotide STING agonist with antitumor activity. Science, 369 (6506). [PMID:32820094] |
3. Yang J, Luo Z, Ma J, Wang Y, Cheng N. (2024)
A next-generation STING agonist MSA-2: From mechanism to application. J Control Release, 371: 273-287. [PMID:38789087] |
4. Zhang H, You QD, Xu XL. (2020)
Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective. J Med Chem, 63 (8): 3785-3816. [PMID:31820978] |